Vaxcyte prices $500 million equity and convertible note offerings
Vaxcyte priced a $500 million equity offering at $64 per share and a $500 million convertible notes offering. Proceeds are expected to support VAX-31 development, manufacturing expansion, inventory and potential U.S. launch preparations.
17M additional shares. 60 per share, a 40% premium to the equity offering price. · Offerings are expected to close Oct. S.
launch preparations.